10 recruiting. 10 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 10 |
| Phase 1 | 5 | Recruiting 5 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure. Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5% - Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Recruiting | Tavo Biotherapeutics | 96 | 2026-10-23 | 2026-11-03 |
| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 156 | 2026-10-07 | 2026-10-22 |
| REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension REGN22530 - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 271 | 2026-09-08 | 2026-09-28 |
| A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml, Placebo of G01 Eye Drops - Primary Open-Angle Glaucoma, Optic Nerve Injury | Phase 2 | Recruiting | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 90 | 2026-03-18 | 2026-08-24 |
| GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma GVB-2001-high dose, GVB-2001-low dose - Primary Open-Angle Glaucoma (POAG) | Phase 1 / Phase 2 | Recruiting | IVIEW Therapeutics Inc. | 6 | 2025-11-19 | 2026-05-04 |
| Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery TimoD implant, Injector system, Timolol eye drops 0.5% - Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Recruiting | EyeD Pharma | 42 | 2025-06-12 | 2026-07-30 |
| Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure - Glaucoma | Phase 2 | Recruiting | Glaukos Corporation | 110 | 2025-06-12 | 2026-09-17 |
| Metformin as a Neuroprotective Therapy for Glaucoma Metformin, Placebo - Glaucoma | Phase 2 | Recruiting | Christopher Kai Shun Leung | 125 | 2025-06-01 | 2025-11-20 |
| Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients Nicotinamide Riboside, Nicotinamide, Nicotinamide Mononucleotide - Glaucoma | Phase 2 | Recruiting | Christopher Kai Shun Leung | 138 | 2025-05-19 | 2025-06-26 |
| Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting Lignocaine-loaded maltose microneedle array patch, EMLA 5% patch - Glaucoma, Cataract | Phase 1 / Phase 2 | Recruiting | Universiti Kebangsaan Malaysia Medical Centre | 154 | 2025-02-17 | 2025-07-18 |
Glaucoma, Open-Angle (5) · Ocular Hypertension (4) · Cataract (2) · Eye Diseases (1) · Lens Diseases (1) · Night Blindness, Congenital Stationary, Autosomal Dominant 1 (1) · Optic Nerve Diseases (1) · Optic Nerve Injuries (1)
Eye Diseases (9) · Ocular Hypertension (6) · Cranial Nerve Diseases (2) · Nervous System Diseases (2) · Cranial Nerve Injuries (1) · Craniocerebral Trauma (1) · Lens Diseases (1) · Optic Nerve Diseases (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Drugs, Investigational (1) · Lidocaine, Prilocaine Drug Combination (1) · Metformin (1) · Niacin (1) · Niacinamide (1) · Nicotinamide Mononucleotide (1) · Ophthalmic Solutions (1) · Starch (1) · Timolol (1) · Transdermal Patch (1) · nicotinamide-beta-riboside (1)
Christopher Kai Shun Leung (2) · Astellas Pharma Global Development, Inc. (1) · EyeD Pharma (1) · Glaukos Corporation (1) · IVIEW Therapeutics Inc. (1) · Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. (1) · Regeneron Pharmaceuticals (1) · Tavo Biotherapeutics (1) · Universiti Kebangsaan Malaysia Medical Centre (1)
United States (4) · China (2) · Hong Kong (2) · Malaysia (1) · Panama (1)
Luis G. Vargas, MD (1) · Lukas Scheibler, PhD (1) · Peirong Lu, MD (1) · Yuanbo Liang (1)